Rani Therapeutics Holdings, Inc.

As of July 1, 2025, Rani Therapeutics Holdings, Inc. has a mildly bearish trend, with mixed indicators showing mild bullishness in MACD and KST but bearish signals in moving averages and Bollinger Bands, while the stock has underperformed the S&P 500 significantly, with a year-to-date return of -64.85%.

As of March 31, 2025, Rani Therapeutics Holdings, Inc. is classified as risky and overvalued due to negative financial metrics, including a Price to Book Value of -10.54 and a year-to-date return of -64.23%, significantly underperforming the S&P 500.

As of June 13, 2025, Rani Therapeutics Holdings, Inc. is in a significant bearish trend, supported by bearish indicators across multiple time frames, despite some bullishness in the monthly RSI.

Rani Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $13 million as of March 2025. The company has a market cap of $29.57 million and does not pay dividends.

As of Jun 18, Rani Therapeutics Holdings, Inc. has a market capitalization of 29.57 million and reported net sales of 1.20 million with a net profit of -54.54 million over the last four quarters. The company has shareholder's funds of 1.99 million and total assets of 36.63 million as of Dec 24.